LSB LakeShore Biopharma
- 2.160
- -0.170-7.30%
- 2.110
- -0.050-2.31%
LakeShore Biopharma News
6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
6-K/A: Report of foreign private issuer [Rules 13a-16 and 15d-16] (Amendment)
6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
6-K: Report of foreign private issuer (related to financial reporting)
20-F: FY2024 Annual Report
NT 20-F: Notice under Rule 12b25 of inability to timely file all or part of an annual report of form 20-F
6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
424B3: Prospectus
6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Analysis
Price Target
No Data
No Data